Artwork

Content provided by Jeffrey Stewart. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Jeffrey Stewart or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Real Talk About the Inflation Reduction Act

28:39
 
Share
 

Manage episode 413029766 series 2286377
Content provided by Jeffrey Stewart. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Jeffrey Stewart or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

The Inflation Reduction Act (IRA), signed into law by President Joe Biden in August 2022, brings significant changes to the U.S. pharmaceutical market as it rolls out over the next 10 years.
Today we dive deep into the IRA with Tiffany McCaslin, Managing Director, Value, Access and Health Outcomes at Syneos Health. Drawing from her extensive background in healthcare policy and industry strategy, Tiffany offers invaluable insights into the practical implications of this landmark legislation for the pharmaceutical industry.

From dissecting the intricacies of price negotiation to unraveling the complexities of data collection requirements, this episode provides a clear roadmap for pharmaceutical companies and life sciences firms navigating the post-IRA era.

For more from our Value & Access experts, check out these insights:

BLOG: Industry Cheers “Co-Pay Accumulator” Ruling, Should Prep for What’s Next

Potential Impact of European Pharma Legislation on Commercialization and Access of New Therapies

BLOG: What Can We Learn From ICER's New Value Framework

Syneos Health Podcast | Market Access for Weight Loss Drugs

MM+M Podcast | Gaining Access and Delivering Pull-Through in IDNs and Key Accounts

BLOG: What ICER’s Draft Sickle Cell Disease Report Means for CGT Pricing
The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.
If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health.
Like what you’re hearing? Be sure to rate and review us!
We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

  continue reading

140 episodes

Artwork
iconShare
 
Manage episode 413029766 series 2286377
Content provided by Jeffrey Stewart. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Jeffrey Stewart or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

The Inflation Reduction Act (IRA), signed into law by President Joe Biden in August 2022, brings significant changes to the U.S. pharmaceutical market as it rolls out over the next 10 years.
Today we dive deep into the IRA with Tiffany McCaslin, Managing Director, Value, Access and Health Outcomes at Syneos Health. Drawing from her extensive background in healthcare policy and industry strategy, Tiffany offers invaluable insights into the practical implications of this landmark legislation for the pharmaceutical industry.

From dissecting the intricacies of price negotiation to unraveling the complexities of data collection requirements, this episode provides a clear roadmap for pharmaceutical companies and life sciences firms navigating the post-IRA era.

For more from our Value & Access experts, check out these insights:

BLOG: Industry Cheers “Co-Pay Accumulator” Ruling, Should Prep for What’s Next

Potential Impact of European Pharma Legislation on Commercialization and Access of New Therapies

BLOG: What Can We Learn From ICER's New Value Framework

Syneos Health Podcast | Market Access for Weight Loss Drugs

MM+M Podcast | Gaining Access and Delivering Pull-Through in IDNs and Key Accounts

BLOG: What ICER’s Draft Sickle Cell Disease Report Means for CGT Pricing
The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.
If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health.
Like what you’re hearing? Be sure to rate and review us!
We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

  continue reading

140 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide